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Sociopolitical and economic climates between 1950 and 1975 favored the funding of cancer 
research, attracted imaginative policy makers, encouraged investigators, and generated new 
knowledge for clinical application. Important advances during this period include the ' 
discovery that DNA alteration is requisite for carcinogenesis and that DNA repair processes 
are important deterrents in the development of cancer. The better understanding of the 
histogenesis of epidermal cancer and melanoma has potential clinical value. More easily 
grasped is the progress made in the therapeutic control of mycosis fungoides and epidermal 
cancer. Complete control of epidermal cancer is now a foreseeable reality. 
The quarter century from 1950 to 1975 had a 
propelling impact on biomedical science in general 
and, as a consequence, a comparable impact on 
dermatology and its related divisions. Sociopoliti-
cal and economic factors determined how much 
funding went into the biomedical research that 
accounted for the magnitude of this impact, but 
the positions of science and the states of knowledge 
at that time determined the progress of research 
and accounted for its quality. The period began 
with "free-wheeling" research which created new 
positions for science as new discoveries were gen-
erated from basic research. During the later years of 
the period, wider clinical applications of those dis-
coveries for the control of disease were emphasized. 
The advances of the period can be judged by the 
brilliance of the discoveries themselves and the 
technologic sophistication behind them as well as 
by their contributions to the control of disease, the 
promotion of health and longevity, and the en-
hancement of the comforts of living. A physician 
probably sees scientific advancement mostly in 
terms of its impact on disease and health; certainly 
this bias is apparent in my assessments. However, 
other criteria are also important since to sustain 
our progress against disease, we must progress in 
the science of planning for research, both "basic" 
and "applied." We are hopeful that biomedical 
discovery and development will be as valid and 
productive during the final quarter of this century 
as they were during the third quarter. 
When Congress founded the National Cancer 
institute in 1937, theories and hypotheses about 
che nature of cancer had already been formulated 
:1 J. The importance of heredity in cancer suscep-
'.ibility was recognized, but the interrelation be-
. ween cancer cells and the host was not as fully 
lppreciated as it is today. Hence the findings 
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of the past 25 years which elucidated these re-
lations are a very important component of on-
cologic progress. 
A certain climate conducive to research in cu-
taneous oncology in 1950 was in large measure 
nurtured by the leadership of the National Cancer 
Institute. Its director, John R. Heller, was a 
dermatosyphilologist who had directed this coun-
try's successful and intensive treatment program 
against syphilis during W orld War II and who 
quipped that he turned his attention to cancer 
after the attack on syphilis had knocked the "h" 
out of chancre. His firm endorsement of and 
encouragement to dermatologic research were later 
maintained and implemented by the perceptive 
policies of Kenneth M. Endicott, the Institute's 
next director. C. Gordon Zubrod, the Institute's 
director of intramural research during those years, 
recognized that the mechanisms which control the 
growth of integumental systems were relevant to 
neoplastic systems as well and fostered dermato-
logic research as part of the Institute's intramural 
program. The visionary policies of these men were 
important to the progress of dermatologic research 
and cutaneous oncology during this period. 
In this presentation, I shall limit my evaluation 
of the progress in cutaneous oncology to only a few 
of the events which changed the attitudes toward 
and direction of the three major categories of 
cutaneous cancer from 1950 to 1975: (1) epidermal 
cancer, the most common of all human cancers; (2) 
melanoma, the next most common skin cancer and 
probably the most dreaded; and (3) a cutaneous 
lymphoma, mycosis fungoides, relatively uncom-
mon but always potentially lethal. This review can 
best be covered under the traditional headings of 
etiology, mechanisms of carcinogenesis, and ther-
apy. 
ETIOLOGY 
The capability to alter DNA directly or in-
directly is probably the common property of all 
carcinogenic agents. This realization is as impor-
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tant to an understanding of the mechanisms of 
carcinogenesis as it is to characterizing etiologic 
agents. By 1950, the major etiologic agents respon-
sible for epidermal cancer in man had already been 
identified. This was not and still is not true for 
melanoma and the lymphomas. 
Ultraviolet radiation has long been recognized as 
the major cause of most epidermal skin cancers in 
man. However, although the anatomic sites of 
actinic keratoses, squamous cell carcinomas, and 
basal cell carcinomas are generally those areas 
most exposed to actinic radiation, some anatomic 
sites of basal cell carcinoma do not fit into such an 
association [2]. Therefore, etiologic factors other 
than actinic radiation appear to induce basal cell 
carcinoma, but what they are is still not known. 
This is also true in the hereditary forms of epider-
mal cancer. For example, in xerodermal pigmen-
tosum the most frequent type of lesion is a squa-
mous cell cancer which seems to result solely from 
exposure to ultraviolet radiation. In the nevoid 
basal cell carcinoma syndrome, however, the le-
sions appear on covered as well as on exposed body 
areas, but not so often. 
Markedly diminished use of arsenic both in 
agricultural insecticides and in drug preparations 
has been associated with the virtual disappearance 
of clinically recognized new cases of arsenical 
cancers. In the past, exposure to tar and tar 
products has been associated with skin cancer, but 
the actual frequency of this association encoun-
tered clinically seems to have been and remains 
minimal. 
Since 1950 no significant new etiologic factors in 
epidermal carcinogenesis have emerged; hence the 
incidence of epidermal cancer in the future should 
remain stable unless exposures to ultraviolet radia-
tion change. 
Although the carcinogenic stimulus which ac-
counts for melanoma in man remains obscure, it is 
now reliably produced in guinea pigs by topical 
applications of chemical carcinogens (W. H . Clark, 
personal communication ). Chronic trauma has 
been discounted as a causative event, but recent 
epidemiologic studies made in both the northern 
and southern hemispheres have suggested that 
light plays a role through its enigmatic influence 
on cutaneous melanocytes [3]. According to these 
studies, the frequency of melanomas increases 
sharply on exposed body areas. This increase is 
most marked in geographic areas towards the 
earth's equator. 
The causative factors of cutaneous lymphoma 
remain unknown. An important first clue to its 
etiology is the association of its frequency with 
immunodeficiency states [4]. No such association 
has been made in regard to the lymphoma, mycosis 
fungoides, however. 
MECHANISMS OF CARCINOGENESIS 
Since carcinogenesis has been fully reviewed by 
Yuspa et al [5], the interpretation that follows is 
limited to some biologic parameters which seem 
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important in defining the cellular and tissue reac-
tion patterns which arise during the development 
of human skin tumors from microfocal begin-
nings to clinically definable diseases. After a 
carcinogenic stimulus impinges on a cell, the 
cell undergoes a neoplastic transformation and 
replicates into societal populations. A relation 
develops between these new cell populations and 
the host, which determines the quality and magni-
tude of the disease. All of these steps must be 
accurately defined before the pathologic events of 
carcinogenesis can be understood and a rational 
position for therapeutic management of the le-
sions can be formulated. During the past 25 years, 
important advances towards the attainment of 
these critical clinical objectives have been made. 
Studies of epidermal tumors caused by actinic 
radiation have led to new theories on the molecular 
basis of carcinogenesis. In a series of epochal 
discoveries [6], Cleaver showed the importance of 
DNA repair in the control of epidermal cancer 
caused by ultraviolet light. What facilitates the 
emergence of malignant cells after DNA damage, 
however, is not yet known. Neither do we know 
why squamous cell cancers and basal cell cancers, 
two tumor types with distinct morphologic and 
behavioral differences, sometimes emerge after 
exposure to a common carcinogenic stimulus. 
According to one hypothesis, basal cell cancers 
result when the normal epidermal cell loses its 
ability to mature and keratinize [7]. This hypothe-
sis is compatible with the histologic finding of 
nonkeratinizing cysts within basal cell tumors and 
of nonkeratinizing palmar pits in the nevoid basal 
cell carcinoma syndrome. In such cases, tumor 
cells retain their normal germinative function but 
fail to mature. Otherwise they remain normal, that 
is, they depend upon the stromal elements of 
supportive cutaneous connective tissue for survival 
[8] . This may explain the nonaggressive character 
of basal cell tumors and their failure to metastasize 
to distant sites. The fact that keratinization occurs 
in basal cell tumors transplanted autologously to 
new cutaneous sites and in tumor explants grown 
in long-term culture [9] indicates that under cer-
tain conditions the dominant characteristic of the 
tumor cell, its failure to mature, is reversible. Thus 
far, however, these findings have not facilitated the 
development of new pharmacologic approaches to 
therapy, mainly because the conditions needed to 
induce keratinization have not been biochemically 
identified. 
The studies of Clark on the histokinetics of 
melanoma evolution, first presented at the Sympo-
sium on the Biology of Skin in 1966 [10], are still 
the most important advance on the pathogenesis 
of this tumor. According to these studies, specific 
histologic patterns characterize the development 
of melanomas in the skin and help to determine 
the inherent malignancy of the lesions and the 
degree of containment that can be achieved by 
the host's immunoinflammatory systems. This 
knowledge, in turn, enables us to select the 
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most effective therapy. In a more recent pub-
lication [11], Clark et al apply specific histo-
logic criteria to these interpretations. 
Some recent findings on mycosis fungoides may 
help to improve our knowledge of how this lym-
phoma develops. The lymphocytoid cell with ser-
pentine nucleus, identified by Lutzner and Jordan 
[12], apparently serves to identify the lymphoma 
as mycosis fungoides and to distinguish it from 
other lymphomas; but its precise nature has not 
been clarified. Found in inflammatory cellular 
infiltrates in various skin lesions [13] and in tissue 
cultures of normal skin [14], the lymphocytoid cell 
apparently is not a neoplasm. Its function and 
actual role in mycosis fungoides need to be ex-
plained. 
The skin continues to be a popular medium for 
exploring carcinogenesis and the biologic mech-
anisms relating to it. Recognition that the canceri-
zation process may be reversible was probably 
gained mostly from observations of the process in 
the integumental system. For example, the regula-
tory role of both the immune system on the 
development and course of cancers and to a lesser 
extent of the inflammatory system as a part of, or 
apart from, the immune system has been investi-
gated in the skin. The roles of these systems can be 
studied in the clinical lesion of keratoacanthoma 
[15], which has been appropriately labeled a self-
healing squamous cell cancer. Other areas are the 
lesions of early epidermal cancer, melanoma, and 
mycosis fungoides which can be reversed by the 
imposition of delayed hypersensitivity reactions 
[16-18]. 
THERAPY 
Despite the distance to be covered before we can 
claim absolute control, I believe the most evident 
progress has been made in the improved clinical 
control of neoplasia in human skin. Goal-oriented 
efforts have been productive in cancer chemother-
apy and have spin-off applicability to cancers of 
the skin. The lessons in cutaneous oncology 
learned through clinical experience have under-
scored the well-known rule, theoretically obvious 
but sometimes practically ignored, that effective 
therapeutic procedures must be carried out early 
and adequately. 
The single formidable therapeutic weapon intro-
(luced against epidermal cancer has been topical 
; hemotherapy with 5-fluorouracil [19,20 J. Clinical 
t" xperience has shown that if it is used early and 
,.dequately, precancerous keratoses and superficial 
,. pidermal cancers can be completely eradicated. 
. ~his therapy, self-administered by the patients 
·1.emselves, can be safely repeated as often as 
; ecessary to assure that microfoci of early epider-
::lal cancers are obliterated even before clinical 
I tetection. If widely and consistently administered, 
this treatment, therefore, seems to be the means by 
'vhich epidermal cancer can be reduced to an 
nfrequently serious disease. 
Although the potential of immunotherapy 
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against melanoma has been widely explored in 
recent years, the mortality rates have not im-
proved. Cure still depends entirely upon complete 
surgical removal of early lesions. 
Therapeutic treatment of mycosis fungoides has 
substantially improved within the past 25 years. 
Before this, the disease was uniformly fatal, pro-
gressing from the skin and involving the lymph 
nodes and internal organs. Today, because of 
effective therapy applied early and sufficiently, the 
disease can be clinically obliterated, in most cases 
for extended periods. Whether it can be actually 
cured, however, is not yet known. Two treatments 
are responsible for the improved prognosis, whole-
body topical administration of mechlorethamine 
[21] and whole-body administration of high-energy 
electrons [22]. Neither of these measures was 
developed specifically to treat this cutaneous ma-
lignancy. Rather, they applied existing knowledge 
and technology to treat a disease whose nature 
remains obscure. 
FEASIBILITY OF COMPLETE CONTROL 
It is important to realize that the most common 
of all cancers, epidermal cancer, is now almost 
completely controllable when certain requirements 
are met. Because of their appearance on highly vis-
ible integument, epidermal cancers as well as pre-
cancerous keratoses lend themselves to early diag-
nosis and eradication by adequate treatments. 
Moreover, lightly pigmented skin, which is prone to 
develop cancer after chronic exposure to ultraviolet 
light, is easily identified and, in fact, distinguishes 
whole genetic groups. Such people can be advised 
either to avoid exposure to the etiologic agent or to 
protect their skin by using topical preparations 
which effectively absorb those wavelengths of ul-
traviolet light that are responsible for causing skin 
cancer. Thus, epidermal cancer can be successfully 
treated, precancers can be eradicated before reach-
ing more advanced states of malignancy, suscepti-
ble population groups can be identified, and since 
the means to avoid the impingement of the major 
carcinogenic stimulus are available, most epider-
mal cancers are now preventable. The achievement 
of this objective, which has been made possible by 
these measures, is not yet universal. But we can 
hope that the rate of progress against all forms of 
cutaneous cancers achieved within the last 25 years 
will be surpassed in the last quarter of the twen-
tieth century. 
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